Regression of melanoma, but not keratoacanthoma, is associated with increased HLA-B22 and decreased HLA-B27 and HLA-DR1.
Sixty three Caucasian patients with either melanoma, keratoacanthoma or squamous cell carcinoma were human leucocyte antigen (HLA) typed. The regressing tumour groups were compared with their non-regressing counterparts, and the patient groups were compared with a control Caucasian population. Melanoma patients showing histological regression were more likely to be HLA-B22 positive, and HLA-B27 and -DR1 negative, than those without features of regression. When compared with a control population, the group of melanoma patients were more likely to be HLA-B22 positive. Comparison of the group of keratoacanthomas, a self-regressing tumour, and the group of squamous cell carcinomas, a non-regressing tumour, did not show any significant differences in HLA typing.
Lowes
M A
MA
Department of Dermatology, University of Sydney, NSW, Australia.
Dunckley
H
H
Watson
N
N
Crotty
K
K
Cooke
B
B
Barnetson
R S
RS
Halliday
G M
GM
D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000276:immunology; D015235:HLA-B Antigens / Q000235:genetics / Q000276:immunology*; D015796:HLA-B27 Antigen / Q000235:genetics / Q000276:immunology; D015798:HLA-DR1 Antigen / Q000235:genetics / Q000276:immunology; D006801:Humans; D007636:Keratoacanthoma / Q000235:genetics / Q000276:immunology*; D008545:Melanoma / Q000235:genetics / Q000276:immunology*; D009365:Neoplasm Regression, Spontaneous; D012878:Skin Neoplasms / Q000235:genetics / Q000276:immunology*
D015235:HLA-B Antigens; C105903:HLA-B22 antigen; D015796:HLA-B27 Antigen; D015798:HLA-DR1 Antigen